RMB, These investment bankers, that have taken control of Amarin, have almost no experience running a pharmaceutical company. They played around in Europe until they realized the cost was not going to yield return. Not quick enough. How long did it take for them to come to that conclusion? They declared a buy back for short term share price movement. They told us that the timing wasn't right. Now they don't even address it. They said that they entered into a partnership in Europe because they intend to focus on the US market. They said almost nothing about the domestic market on the call. current management is a disaster. I still think the basic science will save our investment. I think this in spite of Alex Denner and crew.
Sleven,
Market Data 
Markets 
AI
